J
Jacob M van Laar
Researcher at Utrecht University
Publications - 215
Citations - 15552
Jacob M van Laar is an academic researcher from Utrecht University. The author has contributed to research in topics: Medicine & Rheumatoid arthritis. The author has an hindex of 49, co-authored 189 publications receiving 12309 citations. Previous affiliations of Jacob M van Laar include University Medical Center Utrecht & James Cook University Hospital.
Papers
More filters
Journal ArticleDOI
2013 classification criteria for systemic sclerosis: An american college of rheumatology/European league against rheumatism collaborative initiative
Frank H J van den Hoogen,Dinesh Khanna,Jaap Fransen,Sindhu R Johnson,Murray Baron,Alan Tyndall,Marco Matucci-Cerinic,Raymond P. Naden,Thomas A. Medsger,Patricia Carreira,Gabriela Riemekasten,Philip J. Clements,Christopher P. Denton,Oliver Distler,Yannick Allanore,Daniel E. Furst,Armando Gabrielli,Maureen D. Mayes,Jacob M van Laar,James R. Seibold,László Czirják,Virginia D. Steen,Murat Inanc,Otylia Kowal-Bielecka,Ulf Müller-Ladner,Gabriele Valentini,Douglas J. Veale,Madelon C. Vonk,Ulrich A Walker,Lorinda Chung,David H. Collier,David H. Collier,Mary Ellen Csuka,Barri J. Fessler,Serena Guiducci,Ariane L. Herrick,Vivien Hsu,Sergio A. Jimenez,Bashar Kahaleh,Bashar Kahaleh,Peter A. Merkel,Stanislav Sierakowski,Richard M. Silver,Robert W. Simms,Robert W. Simms,John Varga,Janet E. Pope +46 more
TL;DR: The ACR/EULAR classification criteria for SSc performed better than the 1980 ACR criteria and should allow for more patients to be classified correctly as having the disease.
Journal ArticleDOI
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative
Frank H J van den Hoogen,Dinesh Khanna,Jaap Fransen,Sindhu R Johnson,Murray Baron,Alan Tyndall,Marco Matucci-Cerinic,Raymond P. Naden,Thomas A. Medsger,Patricia Carreira,Gabriela Riemekasten,Philip J. Clements,Christopher P. Denton,Oliver Distler,Yannick Allanore,Daniel E. Furst,Armando Gabrielli,Maureen D. Mayes,Jacob M van Laar,James R. Seibold,László Czirják,Virginia D. Steen,Murat Inanc,Otylia Kowal-Bielecka,Ulf Müller-Ladner,Gabriele Valentini,Douglas J. Veale,Madelon C. Vonk,Ulrich A Walker,Lorinda Chung,David H. Collier,David H. Collier,Mary Ellen Csuka,Barri J. Fessler,Serena Guiducci,Ariane L. Herrick,Ariane L. Herrick,Vivien Hsu,Sergio A. Jimenez,Bashar Kahaleh,Peter A. Merkel,Peter A. Merkel,Stanislav Sierakowski,Richard M. Silver,Robert W. Simms,John Varga,Janet E. Pope +46 more
TL;DR: The ACR/EULAR classification criteria for SSc performed better than the 1980 ACR criteria and should allow for more patients to be classified correctly as having the disease.
Journal ArticleDOI
Update of EULAR recommendations for the treatment of systemic sclerosis
Otylia Kowal-Bielecka,Jaap Fransen,Jérôme Avouac,Mike O Becker,Mike O Becker,Agnieszka Kulak,Yannick Allanore,Oliver Distler,Philip J. Clements,Maurizio Cutolo,László Czirják,Nemanja Damjanov,Francesco Del Galdo,Christopher P. Denton,Jörg H W Distler,Ivan Foeldvari,Kim Figelstone,Marc Frerix,Daniel E. Furst,Serena Guiducci,Nicolas Hunzelmann,Dinesh Khanna,Marco Matucci-Cerinic,Ariane L. Herrick,Frank J. A. van den Hoogen,Jacob M van Laar,Gabriela Riemekasten,Richard M. Silver,Vanessa Smith,Vanessa Smith,Alberto Sulli,Ingo H. Tarner,Alan Tyndall,Joep Welling,Frederic Wigley,Gabriele Valentini,Ulrich A Walker,Francesco Zulian,Ulf Müller-Ladner +38 more
TL;DR: In this article, the European League against Rheumatism (EULAR) developed a set of recommendations for the treatment of systemic sclerosis (SSc) with attention to new therapeutic questions.
Journal ArticleDOI
Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial
Dominique Baeten,Xenofon Baraliakos,Jürgen Braun,Joachim Sieper,Paul Emery,Désirée van der Heijde,Iain B. McInnes,Jacob M van Laar,Robert Landewé,Paul Wordsworth,Paul Wordsworth,Jürgen Wollenhaupt,Herbert Kellner,Jacqueline E Paramarta,Jiawei Wei,Arndt Brachat,Stephan Bek,Didier Laurent,Yali Li,Ying A Wang,Arthur P. Bertolino,Sandro Gsteiger,Andrew M Wright,Wolfgang Hueber +23 more
TL;DR: Secukinumab rapidly reduced clinical or biological signs of active ankylosing spondylitis and was well tolerated, making it the first targeted therapy that is an alternative to tumour necrosis factor inhibition to reach its primary endpoint in a phase 2 trial.
Journal ArticleDOI
Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial
Dinesh Khanna,Christopher P. Denton,Angelika Jahreis,Jacob M van Laar,Tracy M. Frech,Marina E Anderson,Murray Baron,Lorinda Chung,Gerhard Fierlbeck,Santhanam Lakshminarayanan,Yannick Allanore,Janet E. Pope,Gabriela Riemekasten,Virginia D. Steen,Ulf Müller-Ladner,Robert Lafyatis,Giuseppina Stifano,Helen Spotswood,Haiyin Chen-Harris,Sebastian Dziadek,Alyssa Morimoto,Thierry Sornasse,Jeffrey Siegel,Daniel E. Furst +23 more
TL;DR: Tocilizumab was not associated with a significant reduction in skin thickening and should be investigated in a phase 3 trial before definitive conclusions can be made about its risks and benefits.